You are here: Home: OPU 1 | 2006 : Faculty Disclosures

Faculty

Gary H Lyman, MD, MPH Professor of Medicine and Oncology Director, Health Services and Outcomes Research James P Wilmot Cancer Center University of Rochester Medical Center Rochester, New York Charles L Vogel, MD Medical Director, Cancer Research Network Inc Plantation, Florida

Roundtable Participants

J Michael Glendening Jr, MMSc, PA-C The Oncology Center Orange, California Maureen Major, RN, MS Clinical Nurse Specialist Evelyn H Lauder Breast Center Memorial Sloan-Kettering Cancer Center New York, New York Desiree Grogan, RPA-C Cancer Institute of Long Island Great Neck, New York Julie A Plantamura, RN, MSN, FNPc Board Certified Family Nurse Practitioner North Shore Hematology-Oncology Associates PC East Setauket, New York Enza Esposito Luke, RN, MSN, ONP Oncology Nurse Practitioner Hematology/Oncology Medical Group of Orange County Orange, California

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Postgraduate Institute for Medicine (PIM), Research To Practice and Amgen Inc do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of PIM, Research To Practice or Amgen Inc. Please refer to the official prescribing information for each product or discussion of approved indications, contraindications and warnings.

Note: Cases from the practices of Maureen Major, RN, MS and J Michael Glendening Jr, MMSc, PA-C and interviews with Gary H Lyman, MD, MPH and Charles L Vogel, MD are not included in the print monograph but are discussed on the audio program.

CONTENT VALIDATION AND DISCLOSURES

Postgraduate Institute for Medicine (PIM) and Research To Practice (RTP) assess conflicts of interest with their instructors, planners, managers and other individuals who are in a position to control the content of CE activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM and RTP for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. PIM and RTP are committed to providing its learners with high quality CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Mr Glendening — Consulting Fees: Amgen Inc. Ms Grogan — Consulting Fees: Amgen Inc. Ms Luke — No financial interests or affiliations to disclose. Dr Lyman — Consulting Fees: Genomic Health Inc; Contracted Research: Amgen Inc, Genomic Health Inc, GlaxoSmithKline. Ms Major — Speakers Bureau: Abraxis Oncology, Amgen Inc, Genentech BioOncology. Ms Plantamura — Consulting Fees: Amgen Inc. Dr Vogel — Consulting Fees: Abraxis Oncology, AstraZeneca Pharmaceuticals LP, Pfizer Inc; Speakers Bureau: Amgen Inc, AstraZeneca Pharmaceuticals LP, Eisai Inc, Genentech BioOncology, Genomic Health Inc, Novartis Pharmaceuticals, Roche Laboratories Inc, Sanofi-Aventis, SmithKline Beecham, Wyeth; Contracted Research: Amgen Inc, AstraZeneca Pharmaceuticals LP, Eisai Inc, Genentech BioOncology, Novartis Pharmaceuticals, Roche Laboratories Inc, Sanofi- Aventis, SmithKline Beecham, Wyeth.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

The scientific staff and consultants for Research To Practice are involved in the development and review of content for educational activities and report the following real or apparent conflicts of interest for themselves (or their spouses/partners) that have been resolved through a peer review process: Richard Kaderman, PhD, Neil Love, MD, Douglas Paley, Michelle Paley, MD, Margaret Peng, Lilliam Sklaver Poltorack, PharmD and Kathryn Ault Ziel, PhD — no real or apparent conflicts of interest to report; Sally Bogert, RNC, WHCNP — shareholder of Amgen Inc. Research To Practice receives education grants from Abraxis Oncology, Amgen Inc, AstraZeneca Pharmaceuticals LP, Biogen Idec, Genentech BioOncology, Genomic Health Inc, Roche Laboratories Inc and Sanofi-Aventis, who have no influence on the content development of our educational activities.

The following PIM clinical content reviewers, Jan Hixon, RN, Linda Graham, RN, and Trace Hutchison, PharmD, state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interests related to the content of this CE activity of any amount during the past 12 months.

 

Table of Contents

Top of Page